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Dyskerin is a nucleolar protein involved in several cellular processes. In particular, it is part of 
the pseudouridylation complex and catalyzes the isomerization of specific uridines on 
ribosomal RNA (rRNA) into pseudouridines, guided by small nucleolar RNAs (snoRNAs). Dyskerin 
is also part of the telomerase complex stabilizing the telomerase RNA component (hTR). Loss of 
function mutations in DKC1 cause X-linked Dyskeratosis Congenita (X-DC), a ribosomopathy 
characterized by failure of proliferating tissues and increased susceptibility to cancer. However, 
some human tumors like breast, prostate, liver and lung cancers show increased dyskerin 
expression and worse prognosis. Besides the role of dyskerin as tumor suppressor, literature 
lacks studies analyzing the function of its increased expression in tumors. In this work, we 
generated stable DKC1 overexpression cell lines and studied both the behavioral and the 
molecular effects of higher dyskerin expression. Our findings demonstrated that increasing 
dyskerin levels confers a more aggressive phenotype and increased translational efficiency in 
untransformed mammary epithelial cells (MCF10A). Interestingly, also the activity of highly 
purified ribosomes from MCF10A DCK1 overexpressing cells is significantly increased 
independently on the translation initiation modality. Furthermore, DKC1 overexpression lead to 
an up-regulation of the snoRNAs pool, without causing any changes in the global 
pseudouridylation level of rRNA. Among the snoRNAs pool, the three significantly up-regulated 
snoRNAs are known to target uridines on rRNA. Thus, we quantified the percentage of 
pseudouridines (Ψ) through a LC/MS based method on U1492 on 18S rRNA, U4975 and U1445 
on 28S rRNA respectively. Our results show no significant changes in pseudouridine levels in 
these sites, although basing on the in vitro translation results, a biological role of the slight 
changes we detected cannot be excluded. Finally, in line with our in vitro findings, we observed 
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that patients harboring tumors with higher dyskerin expression have worse prognosis, lower 
disease-free survival and advanced lymph node status respect of patients expressing low 
dyskerin levels. In addition, in the same tumors with higher dyskerin expression, levels of 
SNORA64, SNORA70 and SNORA67 are significantly increased. In conclusion, our work indicates 
for the first time that dyskerin may act as an oncogene in breast cancer, promoting neoplastic 
transformation from early stage and providing ribosomes with a major translation efficiency. 
These effects could possible depend either to the modification of U1445 and/or U1492 on rRNA 







Ribosome biogenesis is a highly regulated cellular process that lead to the production of 
ribosomes, ribonucleoproteic complexes aimed to carry out protein synthesis. The process of 
ribosomes production starts in the nucleolus from the transcription of a unique ribosomal RNA 
(rRNA) precursor, the 45S rRNA, by RNA Polymerase I (RNA PolI) from ribosomal DNA (rDNA) 
genes. rDNA genes are present in approximately 400-tandem repeated copies in human 
genome, localized in the Nucleolar Organizing Region (NOR)1 and transcribed in different 
moments through epigenetic regulation2. RNA PolI starts the transcription of the long 45S rRNA 
precursor by binding to the Upstream Binding Factor 1 (UBF1), followed by the Selectivity 
Factor 1 (SL1) forming the Pre-Initiation Complex (PIC). In the 45S rRNA precursor, each rRNA is 
interposed by two Internal Transcribed Spacer (ITS1 and ITS2) and enclosed by two External 
Transcribed Spacer (5’-ETS and 3’-ETS). rRNAs maturation process occurs through cuts, 
rearrangements and post-transcriptional modifications mediated by specific enzymes leading to 
the formation of mature 18S rRNA, 28S rRNA and 5.8S rRNA. The 5S rRNA is transcribed in the 
nucleoplasm by RNA Polymerase III (RNA PolIII) and then imported in the nucleolus3, as for 
ribosomal proteins (RPs) which genes are transcribed in the nucleoplasm by RNA polymerase II 
(RNA PolII) and imported in nucleolus after being translated4.  Ribosomal biogenesis continues 
with the production of the major ribosomal subunit or 60S, where S stands for Svedberg as the 
unit of measure of sedimentation coefficient, formed by the 28S, 5.8S and 5S rRNAs and 47 RPs, 
and of a minor ribosomal subunit or 40S formed by 18S rRNA and 32 RPs. Both 60S and 40S 
subunits migrate in the cytoplasm to give birth to the mature 80S ribosome5,6 (Figure 1). Once 
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in the cytoplasm, after the removal of the accessories assembly factors, ribosomal functionality 




Figure 1 Schematic representation of ribosomal biogenesis and rRNA modifications 10. 
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Ribosome biogenesis and cell cycle 
 
Ribosomes biogenesis is strictly coordinated with cell cycle progression. Generally, cells 
enhance the production of ribosomes during the G1 phase, since they need to synthesize 
enough cellular components to give birth to two daughter cells in the M phase. In addition, the 
amount of ribosomes produced during the G1 phase is a crucial factor for cell cycle 
progression11. Once cells division occurred, cyclin B phosphorylates TIF1B/SL1 that results 
inactivated, therefore blocking the constitution of the PIC and the transcription of 45S rRNA. 
This fine balance, that involve also UBF and PolI activity, guarantees the correct production of 
RNA precursor and ribosomes1,6,12. Interestingly, several studies demonstrated that cell cycle 
and ribosome biogenesis are regulated by the same oncogenes and tumor suppressor genes5, 
respectively upregulating or down-regulating the production of ribosomes. For example, c-MYC, 
an oncogene overexpressed in several human cancers, can interfere with rDNA transcription at 
several levels: firstly favoring the binding of SL1 to rDNA promoter therefore activating PolI 
transcription, secondly stimulating PolII transcription of RPs genes and finally activating the 
transcription factor TFIIIB which enhance PolIII activity5. Another important pathway is the one 
that involves PI3K/AKT/mTOR and leads to the activation of the protein kinase S6, which 
phosphorylates the short subunit ribosomal protein 6 (RPS6). RPS6 influences the transcription 
of a subclass of mRNAs, called Terminal OligoPyrimidine tract in the 5’ UTR (TOP mRNAs), that 
transcribe fundamental proteins for ribosomal biogenesis, such as elongation factors eEF1A and 
eEF2, known as proto-oncogenes6,13. In addition, mTOR activates UBF and PolI transcription, 
together with PolIII transcription allowing the association between transcription factors TFIIIB 
and TFIIIC to the 5S rDNA promoter and activating TFIIIA. For these reasons mTOR is target of a 
therapy based on rapamycin, used also as anti-cancer agent5,14.  
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Regarding the tumor suppressor control, p53 has a central role. Firstly, p53 is a sensor of 
ribosomal stress and it stabilizes when an unbalance in ribosomes production occurs, causing 
cell cycle arrest. Moreover, some RPs unused for ribosomes production sequester MDM2, that 
is no longer able to bind and send p53 to proteasomal degradation, leading to cell cycle 
arrest11. Another example of p53 direct influence on ribosomal biogenesis, is its ability to inhibit 
SL1 recruitment on rDNA promoter blocking PolI and TFIIIB/PolIII activity5,15.  
Finally, the Retinoblastoma Protein (pRb), in its unphosphorylated form, negatively regulates 
PolI transcription binding both UBF and TFIB, and through its binding with EF2A prevents the 
G1/S passage. The hyperphosphorylated form of pRb causes an up-regulation of ribosomes 










As stated before, 45S rRNA processing to mature rRNAs provides for different cuts and co-
/post-transcriptional modifications due to specific enzymes. These modifications may occur 
both on nucleotides (almost 3% of all rRNA is modified) and bases at specific sites possibly 
altering ribosomal structure, translational capability and ligand interaction9,10,19,20. The best 
characterized modifications in humans are: 1) ribose 2’-O-methylation mediated by the C/D box 
ribonucleoproteins (RNPs) complexes; 2) base methylation carried out by methyltransferases 
(MTases, stand-alone or enzymatic complexes); 3) pseudouridylation of specific uridine 
residues mediated by H/ACA box RNPs complexes; and 4) cytidine acetylation catalyzed by N-
acetyltransferases (NAT)9,10 (Figure 1). Generally, all these modifications confer major rigidity to 
RNA structure, protect RNA from nuclease action, favor a C3’-endo sugar conformation and 
base/nucleotide stacking capabilities9. 
 
Pseudouridylation and dyskerin 
 
Among more than 100 different nucleotides modifications, pseudouridine (Ψ) is the first one 
that has been discovered in 1951 by Cohn and Volking, thereby named the “fifth nucleotide”21. 
At the beginning, the presence of Ψ residues was described in rRNAs, transfer RNAs (tRNAs) 
and small nuclear RNAs (snRNAs), but in recent years thanks to Next Generation Sequencing 
(NGS) techniques as PseudoSeq22, PSI-Seq23, Ψ-Seq24 and CeU-Seq25, pseudouridines have been 
detected in almost all RNA species in eukaryotes [e.g. in small Cajal Body-specific RNAs 
(scaRNAs), small nucleolar RNAs (snoRNAs), microRNAs (miRNAs) and messenger RNAs 
(mRNAs)]26. The reaction of isomerization of specific uridines in pseudouridines is articulated in 
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different passages that may be synthetized in the breaking of the linkage between the N1 of the 
uracil base and the C1’ of the ribose, followed by the formation of a new bond between the 
ribose C1’ and the C5 of the uracil. This reaction of internal transglycosylation causes a 180° 
rotation of the nitrogenous base and the formation of a NH group that allows Ψ to form 
additional hydrogen bonds26,27 (Figure 3).    
 
Figure 3 Example of reaction mechanism of the pseudouridylation reaction catalyzed by PUS126. 
 
Due to the different molecular configuration, pseudouridines are characterized by distinct 
physical properties from uridines, such as increased rigidity of the phosphodiester RNA 
skeleton28, increased strength of Ψ-A bonds and increased thermal stability up to 2°C 9,26,29.  
The pseudouridylation reaction can be catalyzed by both stand-alone pseudouridine synthases 
(PUSes) and by H/ACA RNPs complexes, which will be further described in this context.  
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The H/ACA box RNPs consist of an antisense guide snoRNA and four core proteins: dyskerin, 
which has the catalytic activity, NHP2, NOP10 and GAR1 that have RNA binding and structural 
functions30. The RNPs complex is guided to the specific uridine to be modified by a class of 
snoRNAs, localized in the nucleolus or in Cajal bodies (scaRNAs31) and provided with unique 
sequence features32. These snoRNAs have a complex structure composed by two hairpins 
linked by a hinge (H) region. The first hairpin is indeed followed at the 5’ end by the H box 
ANANNA, where N is intended for any nucleotide and which seems to be important for the 
assembly of the RNP complex. At the 5’ of the second hairpin instead, there is an ACA box 
formed by three nucleotides before the 3’ terminus, which has the function to stabilize the 
entire complex. Guide RNAs displaying these sequence features are therefore named H/ACA 
box snoRNAs. The two antisense motifs located near the hairpins give rise to the 
“pseudouridylation pocket”, which allows the site-specific pairing with uridines that needs to be 
















The catalytic subunit of the RNPs complex is dyskerin, a 58 KDa nucleolar protein encoded by 
the DKC1 gene which sequence, mapping on Xq28 chromosome, is ubiquitous and highly 
conserved in nature34. In fact, DKC1 homologues have been identified in Saccharomyces 
cerevisiae named Cbf535, in rats as Nop5736 and in Drosophila melanogaster as Nop60B37. 
Dyskerin structure is constituted by three different domains: the Dyskerin-like domain (DKCLD) 
present in eukaryotes and archaea with unknown function; the catalytic TruB_N domain and 
the PUA (Pseudouridine synthase and Archaeosine transglycosylase) domain which has a 
common RNA recognition surface allowing the snoRNAs binding38–40. Dyskerin has also nuclear 
localization signals (NLS, lysine rich) and nucleolar localization signals (NoLS) important for 
intracellular localization38,41 (Figure 5).  
 
Figure 5 A) Structure of human dyskerin. Adapted from Rocchi et al42. B) Organization of human dyskerin domains. 
N- and C- terminal red boxes represent lysine-arginine rich NLSs; the DKCLD domain is purple, the TruB_N domain 
in blue, and the PUA domain in green; the pink rod within the TruB_N domain marks the catalytic aspartic acid 





Dyskerin is a pleiotropic protein involved in several cellular processes, the main two being RNA 
modification/processing and telomerase complex stabilization. As described before, dyskerin is 
part of the pseudouridylation complex (Figure 6A) and so participating in the correct 
maturation of rRNAs. On the other hand, dyskerin is part of the telomerase complex, in which it 
stabilizes the human Telomerase RNA (hTR or TERC), characterized by the same H/ACA box 
structure described above (Figure 6B). 
 
 
Figure 6 Graphic representations of human dyskerin complexes. A) Pseudouridylation complex. Adapted from 
Penzo and Montanaro44. B) Telomerase complex. Adapted from Calado and Young45. 
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Ribosome biogenesis, dyskerin and cancer 
 
The relationship between ribosome biogenesis and cancer is well documented in literature. The 
first observation was made by Pianese in 1896, who found that more aggressive tumors are 
characterized by larger nucleoli46. During the years, others studies confirmed that highly 
proliferating tumor cells have an increased need of protein synthesis, therefore leading to 
increased ribosome biogenesis and nucleoli dimension12.  
Focusing on breast cancer, it has been demonstrated that more aggressive forms with mutated 
p53 and pRb pathways are characterized by increased ribosomal biogenesis, larger nucleoli and 




Figure 7 Correlation between tumor suppressor alterations, nucleolar dimension (A) and disease-free survival (B) 





Some enzymes involved in rRNA processing can be altered in cancer, leading to accumulation of 
45S rRNA precursor and increased nucleoli dimension47. Furthermore, p53 or pRb are 
frequently mutated in tumors with higher ribosome biogenesis rate and can interfere with 
rDNA transcription. Moreover, rRNA modifications are altered in different types of cancers also 
leading to defect in translation9,10,26. Finally, RPs themselves are linked to cancer 
development48: for example RPL5 and RPL10 are mutated in multiple cancer types49,50. In 
addition, RPs are characterized by extra-ribosomal functions that are linked with cell 
proliferation, invasion and migration capabilities, apoptosis and cell cycle arrest51. 
Dyskerin, a key protein for ribosomes biogenesis, has been linked to cancer in different tissues. 
The first correlation between dyskerin and cancer was made since germline DKC1 mutations are 
at the basis of the inherited syndrome termed X-linked Dyskeratosis Congenita (X-DC) 
characterized by failure of proliferating tissues and increased susceptibility to cancer52,53. 
Ruggero et al in 2003 reproduced X-DC patients’ phenotype generating hypomorphic mice with 
30% of normal dyskerin levels, indicating a tumor suppressor role for dyskerin as its partial lack 
and/or reduced function lead to cancer onset6,54,55. In X-DC patients as in hypomorphic mice, 
tumor susceptibility has been linked to pseudouridylation defects24,54,56, snoRNAs levels 
perturbation57 without involving the telomerase complex disruption54. 
Although mutations in DKC1 sequence are not so frequent in sporadic cancers58, in vitro models 
of dyskerin reduced levels shed light on impaired cellular translation capabilities, specially of 
IRES-containing mRNAs. Internal Ribosomes Entry Sites (IRES) were discovered in viral mRNAs 
first and successively in some human mRNAs, and are nucleotide sequences where ribosomes 
can start translation independently from the presence of canonical CAP-dependent translation 
initiation factors59,60. Different studies demonstrated that dyskerin-depleted cells have 
defective translation of anti-apoptotic factors as Bcl-xL and XIAP61, tumor suppressor genes as 
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p5362 and p2763, together with increased translation of oncogenic mRNAs such as VEGF and 
Hsp7064.  Furthermore, in 2015 Penzo et al. demonstrated that ribosomes isolated from 
dyskerin-depleted cells have intrinsic defects that alter their translation capabilities, making 
them more unfaithful during translation (impaired translational fidelity), mis-incorporating 
amino acids or not recognizing stop codons60. In the same work, Penzo et al confirmed also the 
elongation defects of these ribosomes, previously mentioned by Jack et al19,60. Taken together, 
these findings show an intricate scenario that links Dyskerin down-regulation to cancer onset, 
underlying its role as tumor suppressor. On the other hand, up to date different studies show 
that DKC1 is significantly amplified or overexpressed in several human cancers and often 
correlated to more aggressive forms and worse prognosis. This is true for example in prostate65, 
liver66, ovary67, lung68, biliary tract69, nervous system70 and breast71  cancers.  Montanaro et al 
demonstrated that tumors’ biopsies from patients with higher dyskerin expression have an 
increased ribosomal pseudouridylation level together with higher hTR expression levels 
compared to tumors’ biopsies with lower dyskerin expression. Furthermore, patients bearing 
dyskerin overexpressing tumors display a worse prognosis compared to patients with tumors 






Figure 8 Dyskerin overexpression correlates with increased levels of 18S and 28S rRNAs pseudouridylation (A), 
stabilization of hTR (B) and lower disease free survival (C) in breast cancer. Adapted from Montanaro et al71. 
 
In the same study, Montanaro et al found no correlation between dyskerin expression and  
nucleolar dimension, defining dyskerin expression as an independent prognostic parameter as 
proxy of tumor malignancy71.  
Literature shows evidences that, not only dyskerin down-regulation, but also dyskerin 
overexpression may play a key role in neoplastic transformation, but the molecular insights are 
still unexplored. In 2011 Alawi et al mentioned that transient overexpression of dyskerin did not 
have remarkable effects in terms of proliferation and telomerase activity (data not shown) in 
both telomerase-positive and negative cells lines72. Interestingly, they demonstrated that 
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dyskerin is required to sustain cellular growth independently from its role in telomerase 
complex and only partially for its involvement in rRNA processing72,73. Finally, the same group 
previously demonstrated the direct correlation between c-Myc and dyskerin expression, 
namely that an increased expression of c-Myc corresponds to higher dyskerin levels, thus 
explaining the increased ribosomes biogenesis and transcription for these types of cancer74. It is 
plausible that in tumors other factors, apart from c-Myc, can be involved in dyskerin expression 
regulation and its role in the development of human cancer needs to be further investigated. 
 
Translational control and cancer 
 
As described before, ribosomes are complexes made by RNAs and proteins, structured in two 
different subunits, 60S and 40S, exported in the cytoplasm to form the mature 80S ribosome. 
The 40S subunit has the mRNA binding site that permits its recruitment on the m7G-CAP 5’ 
structure of the mRNA, which is responsible for the translation initiation. The 60S subunit has 
three RNA binding sites for tRNAs. tRNAs are highly structured small RNAs that bind both amino 
acids and mRNAs to pair them through codon-anticodon sequence recognition and transfer 
specific amino acids from the cytoplasm to the growing peptide. The three tRNAs binding sites 
are named P, A and E sites. The P site is the Peptidyl site and contains the tRNA bound to the 
nascent peptide; the A site, or the Acceptor site, houses the aminoacyl-tRNA with the new 
amino acid to be added to the polypeptide chain; the E site, is the Exit of the completely 
translated protein that is released into the cytoplasm75.  
Translation is structured in four main phases: initiation, elongation, termination and ribosomes 
recycling. The vast majority of cellular mRNAs are translated through the canonical m7G-CAP- 
dependent mechanism76. As for transcription, also for translation initiation is required a Pre-
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Initiation Complex (PIC) formed by the 40S ribosomal subunit, the Eukaryotic translation 
Initiation Factors (eIFs family - eIF1, eIF1A, eIF3, and eIF5), a trimer of eIF2 called Ternary 
Complex (TC), the starting methionyl-tRNA and GTP. The whole complex is called 43S PIC75 
(Figure 9).  
 
 
Figure 9 Graphical representation of m7G-CAP-dependent translation initiation in eukaryots77. 
 
Other members of the eIFs, as eIF4E, eIF4F and eIF4A participating in the recruitment of the 
mRNA forming the 48S PIC. In particular, eIF4A, as a DEAD- box RNA helicase, helps the 40S 
ribosomal subunit in the scanning through the structured 5’-UnTraslated Regions (5’-UTR). At 
this point, the releasing of all the eIFs, determine the beginning of the elongation phase78–80. 
Nearly the 10% of cellular mRNAs utilize a CAP-independent translation initiation mode, the so-
called IRES-dependent translation initiation, in which ribosomes bind directly to the mRNA 
without the need of all the above-mentioned accessory factors. This initiation modality is often 
preferred in stress conditions, e.g. hypoxia, and in many cancer cells76,81. 
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During the elongation phase, tRNAs enter the A site, where the decoding takes place at the 40S 
side (mRNA-codon/tRNA-anticodon), and translocate to the P site where the nascent peptide 
chain extends its amino acids sequence75. To do so, eukaryotic Elongation factors (eEFs) are 
required. These enzymes work in a GTP-dependent manner, hydrolyzing GTP to unlock the 
ribosome and modify its structure to permit tRNA translocation. After that, the tRNA is 
deacylated at the E-site and the new protein is released. Recent findings did not still clarified if 
the exit of the polypeptide and the entrance of a new aminoacyl-tRNA in the A site are 
simultaneous or  not82,83. Lastly, translation termination is determined by the presence of a 
stop codon, which cannot be paired to any anticodon and is recognized by the eukaryotic 
Release Factor 1 (eRF1). eRF1 together with eRF3 mediate the releasing of the newly 
synthetized protein75,84.  
The entire process of translation is tightly regulated and connected with lots of cellular 
pathways; deregulation of each phase paves the way to neoplastic transformation76. 
Noteworthy, each factor involved in translation initiation/elongation/termination can be 
altered and involved in neoplastic transformation. For example, several studies demonstrates 
that eIFs are overexpressed in different types of malignancies and often correlate with patients 
worse prognosis76–78.  The other components of the translation machinery can be also altered 
and usually overexpressed in human cancer cells that take advantage of these alterations to 
satisfy their need of proteins and cellular components. Several translation inhibitors are 
currently in trials for cancer treatment78.   
Beyond the canonical key regulators of translation (Figure 10), other elements regulate this 
process: e.g. miRNAs, non-coding RNAs (ncRNAs), IRES-Trans Acting Factors (ITAFs) and RNA 






Figure 10 Canonical and cis-/trans- regulators of mRNA translation in eukaryots75. 
 
A quite recent review of Truitt and Ruggero describes in detail another class of elements that 
strongly impact on translation, which are called cis-regulators and comprehends 
structural/sequence-related elements of mRNAs and tRNAs or even ribosomes intrinsic 
diversities related to cancer development82. Regarding structural features of mRNAs, 5’-UTRs 
tends to be usually unstructured to be easily translated, but some mRNAs display complex 
secondary structures that inhibit translation; this problem is overcome in cancer by the 
overexpression of the helicase eIF4A that easily unwinds these structures. It is not by chance 
that several oncogenes involved in cellular proliferation (e.g. c-MYC) or angiogenesis (e.g. VEGF) 
have highly structured 5’-UTR77,82. Importantly, also the IRES sequences described above are 
classified as 5’-UTR structural complexities and, as said before, preferred by cancer cells. 
Between sequence-specific 5’-UTR modifications, some mRNAs have Alternative Translation 
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Starts (ATS) that can move the initiation starting point from the canonical Open Reading Frame 
(ORF) to an Upstream ORF (uORF) leading to the production of a different protein82,85. Some 
studies demonstrate that oncogenes and genes involved in fundamental cellular pathways, as 
proliferation, have uORFs and that this initiation modality is frequent in human disease82,86,87. In 
addition, cancer cells developed mechanisms to overcome the inhibition of the use of uORFs as 
translation initiation starts82.  
The oncogenic gene expression is also regulated by the presence of specific sequences at the 3’-
UTR of mRNAs; these regions often contain miRNAs-binding sites or RBP motifs that participate 
in the inhibition of mRNAs translation. Some mRNAs isoforms with shortened 3’UTR lack of 
these binding sites, leading to the loss of miRNAs/RBPs translation inhibition and so to 
increased gene expression: for these reasons, this shorter sequence is preferred in cancer 
cells82,88–90.  
Among the class of RNA involved in cancer development, also tRNAs are singled out. The 
cellular pool of tRNAs is constituted by the so called “isoacceptor” tRNAs, that are tRNAs 
charged with the same amino acids, thought to be in excess in normal conditions82. Recently, 
NGS studies demonstrate that some species of tRNAs are overexpressed in tumor cells, 
implicating that also the “choice” or a modification of tRNAs may have a role in neoplastic 
transformation82,91,92. As explained by Truitt and Ruggero, the overexpression of tRNAs is not a 
mere consequence of the increased protein synthesis request, because only a subset of tRNAs 
is altered and can stimulate translation elongation factors for specific mRNAs82. In addition, the 
tRNAs usage has an intrinsic bias due to the tissue specific differential expression of tRNAs93. 
Moreover, it has been proven that there is a direct correlation between tRNA-codons pool, 
tRNAs expression levels and gene expression, especially for pathways that mediate proliferation 
and cell differentiation82,94. Finally, tRNAs are subjected to modifications that influence their 
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expression: e.g. as cited before, pseudouridylation in tRNAs was among the first to be identified 
in human RNAs and it confers stability to the tertiary structure of the molecule26,95. The 
presence of Ψs in tRNAs codon sequence has been found in several human diseases and, in 
some cases, is causative of non-canonical pairing to mRNAs and amino acid mis-
incorporation26,96.   
Finally yet importantly, the main protagonist of translation process, the ribosome can be  
“specialized” to be an onco-ribosome. For example, the presence of mutated RPs in mature 80S 
ribosomes often confers a functional cellular advantage and it has been well demonstrated that 
ribosomes can “prefer” to translate a subset of mRNAs, especially IRES-containing mRNAs, 
involved in neoplastic transformation48,97.  
The process of translation is heavily complicated; taken together these findings let imagine a 
collaboration between specialized onco-ribosomes (possibly disease/tissue specific?97) that can 
translate preferably specific mRNAs provided with peculiar sequence/structure characteristics 





AIM OF THE WORK 
 
Dyskerin is a nucleolar protein encoded by the DKC1 gene which sequence is highly conserved 
in nature34. Dyskerin is involved in several cellular processes, the main two being RNA 
modification/processing and telomerase complex stabilization. As to the function of RNA 
modification, it is part of the pseudouridylation complex, in which it has the catalytic activity 
necessary to isomerize specific uridines residues to pseudouridines mainly on ribosomal RNA 
(rRNA) and small nuclear RNA (snRNA). In this step, dyskerin is guided by a class of small 
nucleolar RNAs (snoRNAs), localized in the nucleolus or in Cajal bodies (scaRNAs) and provided 
with unique sequence features32. On the other hand, dyskerin is part of the telomerase 
complex in which it stabilizes the human Telomerase RNA component (hTR or TERC). 
Germline DKC1 mutations are at the basis of the inherited syndrome termed X-linked 
Dyskeratosis Congenita (X-DC) characterized by failure of proliferating tissues and increased 
susceptibility to cancer52,53. X-DC associated DKC1 mutations alter dyskerin function leading to 
decreased levels of rRNAs pseudouridylation at specific sites19,98 and reduced hTR stability with 
consequently dysregulated telomerase complex activity99.  
In parallel, several tumors types, like for example breast71, prostate65, liver66, and lung68 
cancers, are characterized by an increased dyskerin expression and worse prognosis. In 
particular, focusing on breast cancer, in a previous study Montanaro et al demonstrated that 
tumors from patients with higher dyskerin expression have an increased ribosomal 
pseudouridylation level together with higher hTR expression levels compared to tumors with 
lower dyskerin expression71. Furthermore, patients bearing dyskerin overexpressing tumors 
display a worse prognosis compared to patients with lower dyskerin levels71.   
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Although several studies demonstrated the role of dyskerin as a tumor suppressor42,53,54,63,100, 
literature lacks of works experimentally testing the effect of dyskerin overexpression. The aim 
of this PhD project is to study both the cellular and the molecular in vitro effects correlated to 




MATERIALS AND METHODS 
 
 
Cell Culture and generation of DKC1 overexpression models 
 
MCF10A were cultured in DMEM 1 g/L glucose supplemented with 250 U/L of insulin, 0,5 μg/ml 
of hydrocortisone, 10 ng/ml of epidermal growth factor, 20% Fetal Bovine Serum (FBS), 2 mM 
L-Glutamine, 100 U/ml Penicillin and 1 mg/ml Streptomycin.  
MCF7 were cultured in RPMI 1640 supplemented with 10% FBS, 2 mM L-Glutamine, 100 U/ml 
Penicillin and 1 mg/ml Streptomycin.  
MDA-MB-231 were cultured in DMEM 4.5 g/L glucose supplemented with 10% FBS, 2 mM L-
Glutamine, 2,5X MEM non-essential amino acids, 100 U/ml Penicillin and 1 mg/ml 
Streptomycin. 
To generate stable DKC1 overexpression cell models, all cell lines were infected with Moloney 
Murine Leukemia Virus (MoMLV) containing control plasmid {pMMLV[EXP]-Bsd(IRES:Bsd) then 
named CTRL)} or hDKC1 sequence {pMMLV[EXP]hDKC1[NM_001363.3]:IRES:Bsd then named 
DKC1 OE}. After the infection cells were selected for at least 10 days with blasticidin (8 μg/ml 
MCF10A; 5 μg/ml MCF7; 14 μg/ml MDA-MB-231), dyskerin overexpression was verified both at 
mRNA (Real-Time PCR) and protein levels (Western Blot). Halved blasticidin concentration was 
added in cell culture media for maintenance. 




RNA extraction and real-time RT-PCR 
 
RNAs were extracted using PureZOL™ RNA Isolation Reagent (Bio Rad), following the 
manufacturer’s specifications. cDNA synthesis was performed starting from 500 ng of RNA (10 
ng for hTR levels evaluation) using iScript™ cDNA Synthesis Kit (Bio Rad) following protocol 
instructions.  
Real-time PCR analyses were conducted with CFX96™ Real-Time detection System (Bio Rad). A 
semi-quantitative Taqman approach (SsoAdvanced Universal Probes Supermix Bio Rad) was 
used to evaluate the expression of DKC1 and b-glucuronidase as endogenous control (Applied 
Biosystems Hs 00154737_m1 and 4326320E, respectively). Regarding hTR levels evaluation a 
Taqman approach was used as described by Yajima et al101. A SYBR green approach 
(SsoAdvanced™ Universal SYBR® Green Supermix Bio Rad) was used to measure relative levels 
of snoRNAs (See Table 1). 
 
Table 1 SnoRNAs primers sequences used for Real-Time PCR validation with a SYBR green approach. 
 
SNORNAs NAME FORWARD 5’-3’ REVERSE 5’-3’ 
SNORA64 GTGTGACTTTCGTAACGGGGA TTGCACCCCTCAAGGAAAGAG 
SNORA63 AGCAGGATTCAGACTACAATATAGC GCTACAGGAGAATAGCAGACAG 
SNORA81 AATTGCAGACACTAGGACCAT GGACATTGGACATTAAGAAAGAGG 
SNORA43 GGGCAAAGAGAAAGTGGCGA GGCCATAAACCATTCTCAGTGC 
SNORA46 TCTTGGTTACGCTGTAGTGC ACTCTATACAGCAACAGCAGAAT 
SNORA5A AGCCGTGTCAAATTCAGTACC GCCCATGAGTCACAGTGTTT 
SNORA44 CATGCAAGAGCAACCTGGAA TATAGGAAAGCTGAGTGGCAG 
SNORA5C AGTGCCCGTTTCTGTCATAGC CAAACTTATCCCCAGGTCCCA 
29 
 
SNORA70 CCGACTGAGTTCCTTTCCACA AGGCTGCGTACACTACCAAG 
SNORA5B AGCCATGTCAAATTCAGTGCCT ACTGTTTCTGTGGCAGTCTTCT 
SNORA12 CAAATGGGCCTAACTCTGCC TCTCTGATGCAGGAAAGGCT 
SNORA38 GTGTCTGTGGTTCCCTGTCTT GGCCTCAAAGTTTCCCAAATCC 
SNORA16B GCTCCAGGTGCTTCCATGTAG TCACCATCAAGGAAAACTGTCACT 
SNORA59 GTATGTTCACGGGGCGATGC TCTACGGGTAACTGAGGCAC 
SNORA29 CATTTGACTACCACATTTTCTCCTA TCCCTCTTCAGATCATGGCAAG 
SNORA62 GGAGTTGAGGCTACTGACTGG AGCGAAAACTTGCCCCTCAT 
SNORA3 AGTCACGCTTGGGTATCGG AGCCAGTGAATAAGGTCAGCA 
SNORA67 TCAGGAAAGTAGCAGCTTGGA CTAAGGAAGGCAGAGGAAAT 
SNORA14B CCCTCTTGGTAGCTTCGTCCTA GACTGAGCCACGGGAGAA 
 
For snoRNAs 64L2, 63L9, 70BL6, 67L1, 43L2 and 12L2, since they have no known target RNA, we 
decided to validate the levels the snoRNAs with homology in the pseudouridylation pocket 
sequence or whole sequence, hypothesizing a correspondence in the modified uridines. 
 
Whole cell protein extraction and western blot analysis 
 
Whole cell protein extraction was performed in lysis buffer [KH2PO4 0.1M pH 7.5, NP-40 1%, 
added with complete protease inhibitors cocktail (Sigma Aldrich) and 0.1 mM b-
glycerolphosphate] for 20 minutes on ice and cleared by centrifugation at 14000 RCF for 20 
minutes at 4 degrees. Protein extract was quantified spectrophotometrically with the Bio-Rad 
Protein Assay (Bio Rad). The same amount of proteins was separated in Laemmli loading Dye 
(2% SDS; 8% glycerol; 62,5 mM TRIS HCL PH 6,8; 0,005% bromophenol blue and 2% b-
mercaptoethanol) by SDS PAGE in a polyacrylamide gel (TGX Stain-Free™ FastCast™ Acrylamide 
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Solutions Bio Rad) in Running Buffer (2,5 mM Tris, 19,2 mM Glycine and 0,1% SDS) at constant 
200V for around 30 minutes. Proteins were then transferred on a PVDF membrane (Amersham 
Hybond P 0.45 PVDF GE) with Transfer Buffer (2,5 mM Tris, 19,2 mM Glycine, 20% MetOH) for 2 
hours using a wet transfer device (Biorad). Dyskerin antibody was purchased from Santa Cruz 
Biotechnology (H-300 sc-48794); β-actin antibody was purchased from Sigma Aldrich (clone AC-
74 No. A2228).  
 
Cell invasion assay 
 
Invasion assays were performed in blind well chambers (Neuroprobe Inc.) according to the 
manufacturer’s instructions, using 13 mm-diameter polycarbonate filters (Neuroprobe Inc.) 
with pore size 8 μm. 5 × 104 cells, DKC1 overexpressing and controls, were seeded in the upper 
compartment in low FBS cell culture medium, [2% for MCF10A and 1% for MCF7 and MDA-MB-
231 CTRL and DKC1 OE], while 20% and 10% FBS (respectively) in cell culture medium were 
placed in the lower compartment. After a 24 hours incubation at 37°C, 5% CO2, filters were 
collected and washed with water, while cells were fixed in absolute ethanol for 1 min. Lastly, 
cells were stained with Giemsa stain (1:10 in water) at RT for 10 min and filters were washed 
again twice with water. The non-invading cells were scraped off with a cotton swab. Cells were 
visualized with a Leitz Diaplan light microscope (Wetzlar Germany) equipped with a video 
camera (JVC, 3CCD, KY-F55B, Jokohama, Japan) at 10× of magnification; five random fields for 






In a single 6-well plate, 100 cells for MCF10A CTRL/DKC1 OE and for MDA-MB-231 CTRL/DKC1 
OE or 250 cells for MCF7 CTRL/DKC1 OE respectively, were seeded. The colony number was 
evaluated 10–12 days later, after overnight fixation in 4% formalin at 4°C and staining with a 
0.5% crystal violet solution in 25% methanol for 30 min. Cells were then washed 3 times in PBS 
and counted. 
 
Generation of mammospheres 
 
1.2 × 104 cells were seeded in ultra-low attachment 6-well plates and cultured in Mammary 
Epithelial Cell Growth Medium (MEGM, Bullet Kit, Lonza). Spheres started forming after 4–6 
days and MS were counted between days 7 and 8 under an inverted microscope at 10× 
magnification. 
 
Telomerase activity assay 
 
Telomerase activity assay was performed following manufacturer’s instruction (S7710 - 
TRAPEZE RT, Sigma Aldrich). In brief, 105 cells were lysed with 200 µl of CHAPS lysis buffer and  
2 µl of each lysate were loaded for the Real-Time PCR analysis. Positive/negative controls and 
standard curve were loaded following protocol’s instruction. Platinum™ Taq DNA Polymerase 
(Invitrogen) was used as antibody mediated hot start Taq polymerase for PCR reaction. Results 




Plasmids preparation and in vitro translation assays 
 
For whole cells system in vitro translation assays, 2 x 105 cells (MCF10A DKC1 OE and CTRL) 
were seeded in 6-well plates. The day after, cells were transfected with 400 ng of the report 
monocistronic transcript pR-LUC-F-LUC (a kind gift from Kim De Keersmacker, Department of 
Oncology, Laboratory for Disease Mechanisms in Cancer, KU Leuven) using Lipofectamine 
RNAiMAX Transfection Reagent (Thermo Fischer), following protocol’s instruction. After 5 
hours, cells were lysed with 500 μl of Passive Lysis Buffer 5X and luminescence were measured 
following the instructions of Dual-Luciferase® Reporter Assay System (Promega).  
For in vitro IRES-mediated translation assays with highly purified ribosomes we used the pR-
CrPV-IRES-F plasmid (a kind gift from Dr. Davide Ruggero, Department of Urology, University of 
California, San Francisco, CA, USA)61.  
To make these plasmids suitable for in vitro transcription, the T7 promoter sequence was 
cloned upstream the luciferase gene after enzymatic digestion of the plasmids with HindIII. 
Capped mRNAs were transcribed from linearized plasmids using AmpliCap-Max T7 High Yield 
Message Maker kit (CellScript, Madison, WI, USA), following supplier’s instructions. 




Human ribosomes from MCF10A, MCF7 and MDA-MB-231 CTRL/DKC1 OE were purified as 
described by Penzo et al102. In brief, cells were lysed with a lysis buffer that allows the isolation 
of the cytoplasmatic fraction from the nuclei and mitochondria. After a short incubation of 10 
minutes at 37° C, which permits ribosomes to finish translation and detach from the mRNAs 
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they were translating, up to 500 μl of the cytoplasmic lysate is loaded on discontinuous sucrose 
gradient and ultracentrifuged for 15 hours. The resulting pellet is resuspended in a suitable 
amount of a storage solution (10 mM Tris HCl pH 7.5, 2 mM magnesium acetate and 100 mM 
ammonium acetate in RNAse free water) and ribosomes were quantified following protocol’s 
indications described in Penzo et al102.  
 
Global pseudouridylation quantification 
 
Evaluation of ribosomal RNA global pseudouridylation was performed through HPLC analysis as 
described by Montanaro et al71. rRNA was extracted by highly purified ribosomes as previously 
described. At least 5 μg of rRNA were digested with 10U of Nuclease P1, ammonium acetate 50 
mM pH 5.5 and ZnCl2 1mM for 1 hour at 37°C. The so obtained nucleotides were 
dephosphorylated by incubating with 1 Unit of alkaline phosphatase (Fluka, Sigma-Aldrich, St 
Louis, MO, USA) for 1 hour at 37°C after the addition of 0.4 vol of 50 mM Tris-base and 0.1 vol 
of 10 mM MgCl2. The final volume of this reaction was 100 μl. The resulting nucleosides were 
then subjected to high performance liquid chromatographic (HPLC) separation in a Beckman 
System Gold Programmable Solvent Module 126 equipped with a detector Module 166 set at 
254 nm (Beckman-Coulter, Fullerton, CA, USA). The column (0.39 × 30 cm) was a reversed-
phase μBondapak C18 (particle size 10 μm) purchased from Waters Associates (Milford, MA, 
USA). Mobile phase conditions were 0.1 M phosphate buffer (pH 6)/methanol, 99:1 (v/v) for 12 
min, 96:4 (v/v) for 13 min, and 85:15 (v/v) for 25 min. Pseudo-uridine and major nucleosides 




SnoRNAs expression array 
 
SnoRNAs expression analysis was performed by Arraystar company using the nrStar™ Human 
snoRNA PCR Array which contains 359 snoRNAs, 7 snoRNA target snRNAs and 4 snoRNP 
complex members. 2-5 µg of total RNA from MCF10A DKC1 OE/CTRL were shipped to Arraystar 
Inc. Experiment and data analyses were performed by Arraystar Inc (Rockville, MD). 
 
SILNAS LC/MS based quantitation of Ψs 
 
The SILNAS-based quantitation of the stoichiometry of Ψs was performed in collaboration with 
Toshiaki Isobe’s group who developed the method described in Yamauchi et al103 (Figure 11). 
 
 






One hundred and seventy breast carcinomas were selected from a series of consecutive 
patients who underwent surgical resection for primary breast carcinoma at the Surgical 
Department of the University of Bologna on the sole basis of frozen tissue availability for DKC1 
mRNA expression determination. Part of the cases were obtained from a previous study71 while 
additional samples were collected after 2011. Data on tumor histological classification, grading, 
size and TNM classification were obtained as described71. Surrogate bioprofile classification of 
the cases on the basis of histological results was performed according to St. Gallen 2017 






DKC1 overexpression confers biological features of the neoplastic phenotype in 
untransformed mammary epithelium cells. 
 
To investigate the effect of dyskerin overexpression in tumors we generated breast cancer 
cellular models inducing stable DKC1 overexpression through a retroviral transduction in three 
cell lines with different basal dyskerin expression representing distinct levels of transformation: 
from lower to higher, MCF10A, MCF7 and MDA-MB-231. Cell lines were infected with the 
MoMLV containing or control plasmid {pMMLV[EXP]-Bsd(IRES:Bsd) then named CTRL: control} 
or hDKC1 sequence {pMMLV[EXP]hDKC1[NM_001363.3]:IRES:Bsd then named DKC1 OE: DKC1 
overexpressing cells} (Figure 12).  
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 Figure 12 Schemes of control (up) and human DKC1 expression plasmids (down). 
 
After selection, we verified that DKC1 had been successfully overexpressed both at mRNA and 
protein levels for all the three cell lines (Figure 13). In general, the greatest increase in dyskerin 








We then performed in vitro assays to evaluate the effect of DKC1 overexpression on invasive, 
stemness and clonogenic potentials. Our results show that increasing DKC1 expression confers 
a more aggressive phenotype, in terms of increased number of invasive cells, number of 
colonies and mammospheres, only in untransformed mammary epithelium cells MCF10A in 
respect of control cells (Figure 14). 
 
Figure 13 A) DKC1 mRNA expression evaluated in Real-Time PCR.   B) Quantification of dyskerin expression after 




Figure 14 A) Invasive potential assay through Boyden chambers. Data were analyzed by unpaired Student’s T-test: 
*P < 0.05; **P < 0.01; ***P < 0.001. B) Stemness potential assay through mammospheres formation. Data were 
analyzed by paired Student’s T-test: *P < 0.05; **P < 0.01; ***P < 0.001.  C) Clonogenic potential assay. Data were 
analyzed by paired Student’s T-test: *P < 0.05; **P < 0.01; ***P < 0.001. 
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DKC1 overexpression induce significant increase of telomerase RNA component 
without influencing telomerase activity. 
 
As mentioned in the Introduction, Montanaro et al demonstrated that breast tumors with 
higher dyskerin expression show an increased stabilization of hTR71. For this reason, we verified 
if dyskerin overexpression influences telomerase complex and activity. We evaluated hTR 
levels, finding a significant increase in MCF10 and MCF7 cells after DKC1 overexpression (Figure 
15A). In addition, to check if there could be effects on telomerase activity, we performed the 
Real-Time PCR based TRAPeze® commercial kit (Sigma-Aldrich cat. No. S7710) on MCF10A DKC1 
overexpressing and controls cells. Our results show no significant changes in telomerase activity 
(Figure 15B). Previously, Montanaro et al demonstrated that dyskerin mRNA levels are stricktly 
related to hTR and that DKC1 silencing in MCF7 cells lead to a drop in telomerase activity71. As 
we discussed before, telomerase activity can be impaired when the fundamental component of 
the complex, hTR, is missing; on the other hand, an increased stabilization of hTR may not be 


























































































































Figure 15 A) Evaluation of hTR levels in Real-Time PCR. Data were analyzed by unpaired Student’s T-test: *P < 0.05; 




DKC1 overexpression lead to an increased translation efficiency in MCF10A cells. 
 
Due to the fundamental role of dyskerin in rRNA processing and maturation and the impairing 
of cellular translating capabilities after DKC1 silencing discussed above (See Introduction)60, we 
tested translational efficiency in our model through an in vitro assay based on the transfection 
of a monocistronic reporter vector containing both Firefly Luciferase (F-LUC) and Renilla 
Luciferase (R-LUC) mRNAs. The measured luminescence is directly proportional to cellular 
translational activity. Interestingly, we found that overexpressing dyskerin induces significant 
increase in translational efficiency (Figure 16).  






























m7G RLuc FLuc 3’
 
Figure 16 mRNA translation efficiency assay on MCF10A DKC1 overexpressing and control cells. Data were 
analyzed by unpaired Student’s T-test: *P < 0.05; **P < 0.01; ***P < 0.001. 
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Ribosomes from MCF10A DKC1 overexpressing show significantly increased 
translational efficiency independently from translation initiation modality.  
 
To further investigate the impact of increased dyskerin levels in translation, we tested highly 
purified ribosomes from MCF10A DKC1 overexpressing and control cells for their translation 
efficiency. We challenged the ribosomes with the bicistronic R-LUC/F-LUC reporter vector to 
test both CAP dependent and independent (IRES mediated) translation102. Interestingly, we 
found that ribosomes from dyskerin overexpressing cells are significantly more efficient in 
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Figure 17 mRNA translation efficiency assay conducted on highly purified ribosomes extracted from MCF10A DKC1 




DKC1 overexpression does not affect global pseudouridylation on rRNA but 
induce a remodulation in snoRNAs expression levels. 
 
In order to investigate the effects of dyskerin overexpression on global pseudouridylation, we 
performed HPLC analysis on rRNA (from highly purified ribosomes). Results showed no 
significant changes in global pseudouridylation in all samples (Figure 18A). However, this result 
does not exclude a possible site-specific modification effect. For this reason, we tested snoRNAs 
expression through a comprehensive expression array, which analyze 359 of both H/ACA and 
C/D boxes snoRNAs, focusing only on the first ones, which guide dyskerin and the 
pseudouridylation complex during its activity (See Introduction). The array showed that in 
MCF10A, DKC1 overexpression lead to a remodulation in snoRNAs expression with a majority of 
up-regulated and a few down-regulated snoRNAs. We focused on the top-20 up-regulated 
snoRNAs (Fold Change from 1,5 to 2,5) and, after Real-Time PCR validation, we found four 
snoRNAs that resulted significantly up-regulated: SNORA64, SNORA70, SNORA67 and SNORA38 
(Figure 18B). We decided to focus only on snoRNAs with known target uridines on rRNAs: 
SNORA64 U1492 on 18S rRNA, SNORA70 U4975 and SNORA67 U1445 on 28S rRNA respectively. 
We then performed LC-MS (SILNAS-MS based quantitation) analyses to quantify site-specific 
pseudouridylation on the corresponding uridine sites on 18S and 28S rRNAs of the selected 
snoRNAs103. Results showed no significant changes in all samples (p value NS), but we measured 
a slight increase on Ψ1692 and Ψ1445 on 18S rRNA (corresponding to less uridines, shown in 
Figure 18C). These findings prompted us to measure a more relevant biological sample, thus we 
analyzed highly purified cytoplasmic ribosomes of MCF10A DKC1 overexpressing cells and 
relative controls. Data shows significant reduction of the percentage of U1445 on 18S rRNA of 
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Figure 18 A) HPLC analysis of rRNA extracted from highly purified ribosomes. Results are shown as fold change of 
DKC1 OE/CTRL cells. B Left) Heat map of all H/ACA box snoRNAs ordered for fold change (DKC1 OE/CTRL) LOG2. 
Green values are for more expressed snoRNAs, red values for less expressed.  B Right) Focus on top 20 up-
regulated snoRNAs in MCF10A dyskerin overexpressing cells from Arraystar expression array analyses (up). 
SnoRNAs expression validated in Real-Time PCR (down). Data were analyzed by unpaired Student’s T-test: *P < 
0.05; **P < 0.01; ***P < 0.001; ****P<0.0001. C) LC-MS analyses of sites U4975 on 28S rRNA, U1692 and U1445 
on 18S rRNA of total RNA samples. Results are shown as percentage of unmodified uridines and were calculated 
from peak intensity (U4975, U1692) or peak area (U1445). D) LC-MS analyses of U1445 on 18S rRNA of highly 




Patients with tumors with higher dyskerin expression have worse prognosis, 
lower disease-free survival and advanced lymph node status respect of patients 
expressing low dyskerin levels. 
 
To check if dyskerin overexpression correlates with more malignant neoplastic phenotype also 
in vivo, we updated data from a breast cancer cases series of 170 patients with primary breast 
carcinoma previously published in Montanaro et al71. We confirmed that patients with higher 
dyskerin expression have a lower Disease-Free Survival (DFS) in respect of patients with 
intermediate/low dyskerin levels (Figure 19A). In addition, we found a significant correlation 
between DKC1 mRNA levels and lymph node status. Consistently with our in vitro results in 
which DKC1 overexpressing untransformed cells acquire greater invasive potential, tumors with 
higher dyskerin expression levels show a lymph node status of N1 or higher (grouped N+) 
(Figure 19B). Furthermore, tumors with higher dyskerin expression present also higher levels of 
the snoRNAs found up regulated in MCF10A DKC1 overexpressing cells (Figure 19C). 
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Figure 19 A) Updated DFS of 170 patients who undergone surgery for primary breast carcinoma at the Sant’Orsola 
Hospital. Previous data were published by Montanaro et al in 200671. B) Correlation with DKC1 mRNA expression 
and lymph node status in the same breast cancer cases group. C) Evaluation of snoRNAs levels in Real-time PCR in 
RNA extracted from tumors derived from the same breast cancer cases group. At this purpose, five samples with 





The aim of this PhD project is to deeply characterize both the molecular and phenotypic 
changes that occur in cells with high dyskerin expression focusing on human mammary 
epithelium.  
Firstly, it is interesting to note that we achieved the best DKC1 overexpression levels in 
untransformed epithelium cells (MCF10A), which harbor in principle the lowest dyskerin 
amount (see Cancer Cells Line Encyclopedia, Broad Institute), underlying that at the basal 
condition our models require different dyskerin expression because of their diverse 
transformation status and their intrinsic differences. It is probably for this reason that 
increasing dyskerin expression confers a more aggressive phenotype only in untransformed 
mammary epithelium cells MCF10A and that in parallel, we observed not significant changes 
(MCF7) or even a “toxic” effect in neoplastic cell models (MDA-MB-231) (See Figure 14). Cells 
that are already transformed and represent an advanced tumor stage may not have benefits of 
even higher dyskerin levels that can disturb their balance. Basing on that, we can state that 
dyskerin overexpression may be an early event occurring in neoplastic transformation of breast 
epithelium, although would be fundamental to confirm these data in alternative models as 
Human Mammary Epithelium Cells (hMEC) systems. hMECs are different cell populations at 
progressive levels of neoplastic transformation stages deriving from the same healthy cells 
obtained from breast reduction intervention. This model would eliminate biases derived from 
various genetic backgrounds. Some experiments in this sense have been conducted and are still 
on going (data not shown). 
Successively, we found that MCF10A DKC1 overexpressing cells are significantly more efficient 
in translation (See Figure 16) and more specifically that DKC1 overexpressing cells make 
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ribosomes more efficient in mRNA translation independently on the initiation modality (Figure 
17). It has been previously reported that dyskerin depletion induce a defect in translation 
elongation19,60; in this sense, our results suggest that DKC1 overexpression may, in contrast, 
enhance the synthetic activity of ribosomes during the elongation phase. Preliminary results 
obtained inhibiting the elongation phase with selective inhibitors, as cycloheximide and 
puromycin, seem to confirm this hypothesis, since the treatment drops the differences 
observed in untreated cells (data not shown). In addition, translation elongation factors are 
altered in many cancer types105,106 and, regarding breast tumors, overexpression of some of 
these factors is predictive of worse prognosis and associated with subtypes stratification105.  
Since results indicate that DKC1 overexpression provide ribosomes with intrinsic different 
characteristics that improve translation efficiency, we investigated what make these ribosomes 
more efficient. Even if there are no changes in global pseudouridylation levels (Figure 18A), we 
found that after DKC1 overexpression the majority of the snoRNAs are up regulated (Figure 
18B). We focused on the target modification sites of the three significantly up-regulated 
snoRNAs: U1492 on 18S rRNA for SNORA64, U1445 and U4975 on 28S rRNA for SNORA67 and 
SNORA70 respectively and thanks to a collaboration with Dr. Toshiaki Isobe’s group of the 
Tokyo Metropolitan University, we analyzed site-specific pseudouridylation. Initially we found 
not significative changes in the levels of pseudouridylation in the analysed sites but it is 
important to consider that, as demonstrated by Dr. Isobe’s group in Taoka et al 98, these sites 
are almost fully pseudouridylated at basal state conditions. However, the decrease in the 
percentage of not-modified uridines observed for some sites (e.g. 1445 on 18S ranged from 6% 
to 3% in DKC1 overexpressing cells) suggested that more important changes may concern 
specific subset of ribosomes. Therefore, to exclude the possible confounding effect of nuclear 
maturing pre-ribosomes, we evaluated highly purified cytoplasmic ribosomes of MCF10A DKC1 
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overexpressing in respect of control cells. In this specific set of ribosomes, we found a 
significant decrease of U1445 on 18S rRNA (shown in Figure 18D) highlighting a possible role of 
this specific pseudouridine on translation elongation efficiency. In support to our hypothesis, 
Abeyrathne et al. recently published Cryo-EM structures of S. Cerevisiae 80S ribosome-eEF2-
GTP complex that show the involvement of U1445 in ribosomes structural changes during the 
elongation phase107.  
In parallel, several works found a role for snoRNAs themselves in human cancers28,108,109. 
Noteworthy, SNORA64 has been found up-regulated in metastatic tumors rather than in 
primary prostate cancer cases109. In addition, data from a group of 994 patients of the Breast 
Invasive Carcinoma study of The Cancer Genome Atlas (TCGA) database show that SNORA64 is 
altered in 5% of cases and, specifically, these alterations are genetic amplification or mRNA up 
regulation. Moreover, patients harbouring these alterations have a significantly shorter disease 





Figure 20 Data from the The Cancer Genome Atlas database for SNORA64 alterations in Breast Invasive Carcinoma. 
cBioPortal for Cancer Genomics. 
53 
 
Finally, we found that our in vitro results have a correspondence in vivo on a primary breast 
cancer cases series available in our laboratory. We updated data from these patients regarding 
DFS, confirming what Montanaro et al previously published in 2006, namely that patients with 
higher dyskerin expression have shorter DFS and worse prognosis than patients with lower 
DKC1 levels. These patients with higher dyskerin expression more frequently display lymph 
node involvement as compared to patients with lower DKC1 expression, in line with our in vitro 
findings, in which DKC1 overexpressing untransformed cells acquire a greater invasive 
potential. Basing on this clinical-experimental concordance, dyskerin overexpression can be 
considered a proxy of tumor aggressiveness. In addition, the fact that tumors with higher 
dyskerin expression have increased levels of SNORA64, SNORA67 and SNORA70 is an important 
result that indicate that the molecular mechanism we characterized in vitro may be also true 





Our in vitro study propose for the first time that dyskerin overexpression may be an early event 
in the neoplastic transformation of mammary epithelium, suggesting a new role for dyskerin as 
an oncogene in breast cancer. Additional experiments are needed to further confirm the 
obtained results by extending the cellular models panel with human Mammary Epithelium Cells 
(hMECs), which nowadays can be considered as the best model to analyze tumor 
onset/progression of human breast epithelium. To our knowledge, this is the first study that 
investigate the effects of dyskerin overexpression in breast cancer.  
Our work also contributes to expand the knowledge on the involvement of dyskerin in protein 
synthesis and ribosomes biogenesis, and lets to the hypothesis that ribosomes from tumor with 
higher dyskerin expression are more efficient in translation of selected mRNAs. In this sense, 
we are currently performing the Clariom S human expression array (Thermo Fisher) comparing 
total RNA and mRNAs that are actively translated (polysomes-bound RNAs) in MCF10A DKC1 
overexpressing and control cells in order to understand how and how much dyskerin influences 
the cellular “translatome”. Finally, in vitro translation experiments indicate that ribosomes from 
dyskerin overexpressing cells are different in translation, probably being characterized by a 
more efficient elongation phase. This result may open to innovative therapeutic strategies 
based on the usage of antibiotics that interfere specifically with the elongation phase of 
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